title: Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies.
abstract: The Israeli Teratogen Information Service prospectively followed up 210 pregnancies with first trimester carbamazepine exposure. Pregnancy outcome was compared with that of two overlapping controls, matched and general (n = 629), exposed to nonteratogenic agents. Our study suggests a twofold increase in the rate of major congenital anomalies (12/160 [carbamazepine] versus 18/560 [general control]; relative risk 2.24; 95% CI 1.1-4.56) and a birth weight reduction of approximately 250 g after in utero exposure to carbamazepine.
authors.affiliation: Israeli Teratogen Information Service, Laboratory of Teratology, Jerusalem, Israel.
authors.forename: O
authors.initials: O
authors.lastname: Diav-Citrin
authors.forename: S
authors.initials: S
authors.lastname: Shechtman
authors.forename: J
authors.initials: J
authors.lastname: Arnon
authors.forename: A
authors.initials: A
authors.lastname: Ornoy
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects* / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine